Acorda shares fall on Biogen partnership |  |
|
Posted by Mary Canady July 1st, 2009 .
| |
| No Comments |
Shares of Acorda Therapeutics Inc. fell Wednesday after the company gave Biogen Idec Inc. overseas rights to the experimental multiple sclerosis drug Fampridine-SR, though investors have been hoping for a buyout, according to a JPMorgan analyst.
See other entries categorized in News, San Diego Union Tribune, Syndication.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
